摘要
抑制Tau蛋白表达展现出改善Tau蛋白病变小鼠模型的行为缺陷的能力,为该病的治疗提供了一个有吸引力的治疗方案。在实验上已实现通过关掉启动子控制人类Tau基因转染,但对于实际人类患者是不可能的。因此,本研究的目的是评估小分子干扰核糖核酸的有效性和他们在大脑的传递以抑制人类Tau蛋白在体内的表达,这可能是人类Tau蛋白病变的一个可选择治疗方案。我们主要使用转基因小鼠的大脑神经元表达P301S-突变的人类Tau基因和隆德中脑细胞验证小分子干扰核糖核酸体外的抑制效应。为了评估体内抑制效应,我们将小分子干扰核糖核酸定向的注入P301S小鼠的脑内,通过免疫化学(AT180、MC1 CP13抗体)来揭示Tau基因的抑制效应。我们发现Accell™SMART的小分子干扰核糖核酸在体外和体内可有效地抑制Tau表达,且不需要特定的投递试剂。单次注射小分子干扰核糖核酸后在小鼠的海马区显示适度的分布。当转染的人类Tau基因小分子干扰核糖核酸出现在在海马区后, NeuN, GFAP, Iba-1, MHC II免疫活性和末端脱氧核苷酸转移酶缺口末端标记的dUTP化验既无神经炎症也无细胞凋亡的出现的迹象。我们的数据表明抑制转染的人类Tau基因小分子干扰核糖核酸可以作为Tau蛋白病变基因疗法的一种潜在工具。
关键词: FTDP-17-tau,体外,体内,P301S转染的人类Tau基因转基因老鼠,RNAi,小分子干扰核糖核酸,tau蛋白病变
Current Gene Therapy
Title:Tau Silencing by siRNA in the P301S Mouse Model of Tauopathy
Volume: 14 Issue: 5
Author(s): Hong Xu, Thomas W. Rosler, Thomas Carlsson, Anderson de Andrade, Ondrej Fiala, Matthias Hollerhage, Wolfgang H. Oertel, Michel Goedert, Achim Aigner and Gunter U. Hoglinger
Affiliation:
关键词: FTDP-17-tau,体外,体内,P301S转染的人类Tau基因转基因老鼠,RNAi,小分子干扰核糖核酸,tau蛋白病变
摘要: Suppression of tau protein expression has been shown to improve behavioral deficits in mouse models of tauopathies, offering an attractive therapeutic approach. Experimentally this had been achieved by switching off the promoters controlling the transgenic human tau gene (MAPT), which is not possible in human patients. The aim of the present study was therefore to evaluate the effectiveness of small interfering RNAs (siRNAs) and their cerebral delivery to suppress human tau expression in vivo, which might be a therapeutic option for human tauopathies. We used primary cortical neurons of transgenic mice expressing P301S-mutated human tau and Lund human mesencephalic (LUHMES) cells to validate the suppressive effect of siRNA in vitro. For measuring the effect in vivo, we stereotactically injected siRNA into the brains of P301S mice to reveal the suppression of tau by immunochemistry (AT180, MC1, and CP13 antibodies). We found that the Accell™ SMART pool siRNA against MAPT can effectively suppress tau expression in vitro and in vivo without a specific delivery agent. The siRNA showed a moderate distribution in the hippocampus of mice after single injection. NeuN, GFAP, Iba-1, MHC II immunoreactivities and the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay showed neither signs of neurotoxicity or neuroinflammation nor apoptosis when MAPT siRNA is present in the hippocampus. Our data suggest that siRNA against MAPT can serve as a potential tool for gene therapy in tauopathies.
Export Options
About this article
Cite this article as:
Xu Hong, Rosler W. Thomas, Carlsson Thomas, Andrade de Anderson, Fiala Ondrej, Hollerhage Matthias, Oertel H. Wolfgang, Goedert Michel, Aigner Achim and Hoglinger U. Gunter, Tau Silencing by siRNA in the P301S Mouse Model of Tauopathy, Current Gene Therapy 2014; 14 (5) . https://dx.doi.org/10.2174/156652321405140926160602
DOI https://dx.doi.org/10.2174/156652321405140926160602 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetics of Bladder-Exstrophy-Epispadias Complex (BEEC): Systematic Elucidation of Mendelian and Multifactorial Phenotypes
Current Genomics Histone Acetylation in Neurodevelopment
Current Pharmaceutical Design 3D-QSAR and Docking Simulation Studies of Some Benzopyrone Derivatives as Inhibitors for Breast Cancer Stem Cell Growth via PGlycoprotein Mediated Efflux
Current Bioinformatics Canine Nutritional Model: Influence of Age, Diet, and Genetics on Health and Well-Being
Current Nutrition & Food Science Human Endometrial and Ovarian Cancer Cells: Histone Deacetylase Inhibitors Exhibit Antiproliferative Activity, Potently Induce Cell Cycle Arrest, and Stimulate Apoptosis
Current Medicinal Chemistry Ameliorative Potential of Glycyrrhiza glabra Extracts on Memory Impairments in Stress Triggered Rats
Current Traditional Medicine Influence of CYP3A5 Polymorphism on the Pharmacokinetics of Psychiatric Drugs
Current Drug Metabolism Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca<sup>2+</sup> Permeable α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
CNS & Neurological Disorders - Drug Targets Nicotinic Acetylcholine Receptor Interaction with β -Amyloid: Molecular, Cellular, and Physiological Consequences
Current Alzheimer Research MMP-9 Inhibitors in the Brain: Can Old Bullets Shoot New Targets?
Current Pharmaceutical Design Perspectives on Brain-Targeting Drug Delivery Systems
Current Pharmaceutical Biotechnology Physiological Roles of Neuronal Nicotinic Receptors Subtypes: New Insights on the Nicotinic Modulation of Neurotransmitter Release, Synaptic Transmission and Plasticity
Current Topics in Medicinal Chemistry Imaging of P-glycoprotein Function and Expression to Elucidate Mechanisms of Pharmacoresistance in Epilepsy
Current Topics in Medicinal Chemistry Anticholinergic Effects of Oral Antipsychotic Drugs of Typicals Versus Atypicals Over Medium- and Long-Term: Systematic Review and Meta-Analysis
Current Medicinal Chemistry Role of NUCB2/nesfatin-1 as a Possible Biomarker
Current Pharmaceutical Design High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
Current Drug Targets Natural Products of Dietary Origin as Lead Compounds in Virtual Screening and Drug Design
Current Pharmaceutical Biotechnology REM sleep and its Loss-Associated Epigenetic Regulation with Reference to Noradrenaline in Particular
Current Neuropharmacology Neuropharmacological Profile of Gamma-Decanolactone on Chemically-induced Seizure in Mice
Central Nervous System Agents in Medicinal Chemistry Functional Connectivity in a Rat Model of Alzheimer's Disease During a Working Memory Task
Current Alzheimer Research